A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ONO-7057-08/20180015)

A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ONO-7057-08/20180015)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224738

Enrollment

460

Registered

2019-06-20

Start date

2019-04-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

investigational material(s) Generic name etc : Carfilzomib, Lenalidomide, Dexamethasone INN of investigational material : Carfilzomib, Lenalidomide and Dexamethasone Therapeutic category code : 429 Ot

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Subject has multiple myeloma with documented relapse or progression after most recent myeloma treatment. 2.Subject has measurable disease lesion defined in the protocol. 3.Subjects must have received at least 1 but not more than 3 prior lines of therapy for multiple myeloma.

Exclusion criteria

Exclusion criteria: 1.Waldenstrom macroglobulinemia 2.POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes). 3.Plasma cell leukemia.

Design outcomes

Primary

Measure	Time frame
efficacy	—

Secondary

Measure	Time frame
efficacy other Progression free survival (PFS), Convenience as measured by the Patient-reported convenience with carfilzomib dosing schedule question etc.	—

Countries

Europe, Japan, North America

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026